Contact immunotherapy-induced Renbök phenomenon in a patient with alopecia areata and psoriasis vulgaris

European Journal of Dermatology

Volumn 20, Issue 1, 2010, Pages 126-127

  Ito, Taisuke ^a   Hashizume, Hideo ^a   Takigawa, Masahiro ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; BETAMETHASONE BUTYRATE PROPIONATE; BETAMETHASONE DERIVATIVE; GAMMA INTERFERON; HLA DQB1 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 8; MESSENGER RNA; SQUARIC ACID DIBUTYL ESTER; THYROID ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACANTHOSIS; ADOLESCENT; ALOPECIA AREATA; CASE REPORT; CONTACT IMMUNOTHERAPY; CYTOKINE PRODUCTION; ERYTHEMA; FEMALE; GENE LOCUS; HAIR LOSS; HEMATOLOGY; HUMAN; IMMUNOTHERAPY; LETTER; PARAKERATOSIS; PHYSICAL EXAMINATION; PSORIASIS VULGARIS; RENBOK PHENOMENON; SIDE EFFECT; STAINING; TREATMENT RESPONSE;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ALOPECIA AREATA; CALCITRIOL; CYCLOBUTANES; DERMATOLOGIC AGENTS; FEMALE; HAIR; HUMANS; IMMUNOTHERAPY; PSORIASIS;

EID: 76749130581     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2010.0819     Document Type: Letter

References (6)

1. Happle R, van der Steen PHM, Perret CM. The Renbök phenomenon: An inverse Köbner reaction observed in alopecia areata. Eur J Dermatol 1991; 1: 228-30.
2. van de Kerkhof PC, Schalkwijk J. Psoriasis. In: Callen JP, Horn TD, Mancini AJ, Salasche SJ, Schaffer JV, Schwarz T, Stingl G, Stone MS, eds. Dermatology. London: Elsevier, 2008: 115-35.
3. Orecchia G, Marelli MA, Perfetti L, Rabbiosi G. Alopecia areata: more on topical sensitizers. Dermatologica 1990; 180: 57-9.
4. Hoffmann R, Wenzel E, Huth A, et al. Cytokine mRNA levels in Alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone. J Invest Dermatol 1994; 103: 530-3.
5. Ito T, Meyer KC, Ito N, Paus R. Immune privilege and the skin. Curr Dir Autoimmun 2008; 10: 27-52.
6. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23.